Glucagon-like peptide-1 (GLP-1), secreted by L cells in the small intestine, assumes a central role in managing type 2 diabetes mellitus (T2DM) and obesity. Its influence on insulin secretion and gastric emptying positions it as a therapeutic linchpin. However, the limited applicability of ...
The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts with GLP-1, a key hormone that pla...
Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment...
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that promotes healthy insulin signaling, regulates blood sugar levels, and suppresses appetite. Consequently, numerous GLP-1 receptor (GLP-1R) stimulating drugs have been developed and approved by the US Food and Drug Administration (FDA) ...
Glucagon like peptide-1 receptor agonists (GLP-1RAs) are emerging glucose control drugs, which are widely used in the treatment of T2MD in recent years. Due to the wide distribution of GLP-1R, GLP-1RAs also have a wide range of pharmacological effects. At present, existing GLP-1RAs mainl...
Zhong-Min LiuResearch Center for Translational MedicineExpert Opinion on Investigational DrugsTomlinson, B., Hu, M., Zhang, Y.Z., Chan, P., Liu, Z.M., 2016. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin. Investig. Drugs 25, 1167-1179....
Hölscher C. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson’s and Alzheimer’s disease clinical trials: a revolution in the making?Neuropharmacology. 2024;253:109952. doi: 10.1016/j.neuropharm.2024.109952
P. (2014). The Glucagon-like Peptide-1-Based Therapeutics Exenatide and Saxagliptin Did Not Cause Detrimental Effects on the Pancreas in Mice, Rats, Dogs, and Monkeys. Diabetes Obes Metab. doi: 10.1111/dom.12294Roy D, Chadwick KD, Tatarkiewicz K, et al. The glucagon-like peptide-1-based...
The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts with GLP-1, a key hormone that pla...
does not significantly reduce macrovascular morbidity and mortality. Among emerging anti-diabetic candidates, glucagon like peptide-1 (GLP-1) based therapies carry special cardiovascular implications, exerting both direct as well as indirect effects. The direct cardiovascular effects of GLP-1 and its ana...